Market Overview - Major indexes such as the Dow, S&P, and Nasdaq are near all-time highs, with the Russell 2000 at year-to-date highs, indicating a significant market recovery since early April [1][2] - From the lows on April 7, 2023, the Dow has increased by 25.9%, the S&P by 36.2%, the Nasdaq by 49.1%, and the Russell 2000 by 39.7% [2] Historical Context - The S&P 500 experienced a 23.3% increase last year, marking the second consecutive year of over 20% gains, a rare occurrence since 1995-1996 [4] - The historical performance of the S&P during the dot-com boom saw substantial annual gains, with a total increase of 220% over five years [5] Current Economic Indicators - Recent inflation data shows core inflation at 3.1% year-over-year, with the Producer Price Index easing to 2.8% [10][11] - The Federal Reserve is expected to cut interest rates, with nearly 100% odds of a cut, potentially by 50 basis points [13][14] Earnings Outlook - Earnings growth remains strong, with S&P earnings up 12.5% in Q2 2025 and forecasts of continued growth in subsequent quarters [16][17] - Despite previous concerns over tariffs and recession, aggregate earnings estimates indicate resilience and growth potential [17] Small-Cap Performance - The small-cap sector is experiencing a rally, supported by anticipated interest rate cuts and favorable tax provisions from recent budget legislation [18][20] - Small-caps are expected to benefit significantly from lower borrowing costs and immediate expensing of capital expenditures [19][20] Technology Sector - The current market is witnessing a tech boom driven by Artificial Intelligence (AI), which is anticipated to be transformative across various industries [7][8] - The AI trade is supported by real earnings and growth potential, contributing to a positive market outlook [8] Investment Strategies - Proven stock-picking strategies, such as focusing on Zacks Rank 1 Strong Buy stocks, have historically outperformed the market [23][24] - Strategies targeting small-cap growth and stocks making new highs have shown significant returns compared to the broader market [28][29]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Allegations - The complaint claims that during the class period, C3.ai did not disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - The lawsuit alleges that C3.ai would struggle to achieve its profit and growth potential due to these undisclosed issues [2]. Financial Impact - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by October 21, 2025, to serve as lead plaintiff [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].

Group 1 - UBS raised its price target on c3.ai to $17 from $16 while maintaining a Neutral rating due to ongoing uncertainty regarding growth trajectory and execution risks [1] - The firm expressed caution regarding FY27 revenue outcomes, with investor expectations ranging from flat growth to mid-20% expansion [1] - c3.ai's Q1 miss was attributed to execution issues on large deals rather than widespread weakness, but new leadership changes have introduced uncertainty [1] Group 2 - UBS noted that the FY26 revenue framework of $290 million to $300 million seemed conservative, but the lack of a finalized strategy under the new CEO could disrupt performance over several quarters [2] - The firm kept its FY26 revenue estimate unchanged at $299 million [2] - Visibility into the second half of FY26 and into FY27 remains limited, and despite negative investor positioning, UBS prefers to remain cautious until more clarity is available [2]

Core Insights - C3.ai is a leading provider of enterprise AI software, helping organizations accelerate digital transformation with over 130 AI applications tailored for various industries [1][2] - The company reported a quarterly loss per share of $0.37, slightly better than analyst expectations, but its revenue of $70.3 million missed consensus estimates by 19% year-over-year [5][6] - Analysts have sharply revised their revenue forecasts for FY2026 down to $323 million from a previous estimate of $420 million, indicating significant challenges ahead [6] Financial Performance - C3.ai's total revenue for the last fiscal year was $310.8 million, with a gross profit of $192.9 million, but operating expenses reached $460.3 million, resulting in an operating loss of $267.4 million and a net loss of $268.3 million [7] - Despite these losses, C3.ai maintains a strong cash position with $743 million in reserves and no debt, providing a solid foundation for future investments [7] Market Performance - C3.ai shares have experienced a 32% decline over the last three months and a 23% decline over the past 52 weeks, contrasting with the Russell 2000 benchmark, which has shown modest gains [3][4]

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud impacting investors between February 26, 2025, and August 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management provided misleading positive statements while concealing adverse facts about the company's growth, particularly regarding the health of its CEO and its impact on deal closures [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health [2]. - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud impacting investors between February 26, 2025, and August 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management made misleading statements about the company's growth while concealing adverse facts, particularly regarding the health of its CEO, which affected the company's ability to close deals [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and lowered its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health [2] - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses in C3.ai during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth potential, particularly related to CEO Thomas M. Siebel's health issues [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased C3.ai securities between February 26, 2025, and August 8, 2025 [1]. - Investors have until October 21, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against C3.ai - The lawsuit claims that C3.ai misled investors by presenting an overly optimistic revenue outlook while downplaying risks associated with the CEO's health [3]. - On August 8, 2025, C3.ai announced disappointing preliminary results for Q1 of fiscal year 2026 and lowered its full-year revenue guidance, attributing this to poor sales performance and CEO health concerns [4]. - Following this announcement, C3.ai's stock price dropped by more than 25% [4].

Core Points - The article highlights the upcoming deadline of October 21, 2025, for investors to file a lead plaintiff motion in a securities class action lawsuit related to C3.ai, Inc. [1] Company Summary - The lawsuit is on behalf of investors who purchased C3.ai, Inc. securities between February 26, 2025, and August 8, 2025, which is referred to as the "Class Period" [1]

Core Points - C3.ai, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth and the impact of its CEO's health on business operations [1][2] - The company announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to leadership reorganization and the CEO's health [1] - Following the announcement, C3.ai's stock price dropped approximately 25.58%, from $22.13 on August 8, 2025, to $16.47 on August 11, 2025 [1] Shareholder Information - Shareholders who purchased shares during the class period from February 26, 2025, to August 8, 2025, are encouraged to register for the class action and can do so without any cost or obligation [2] - The deadline for shareholders to seek lead plaintiff status is October 21, 2025 [2] Legal Representation - The Gross Law Firm is representing the shareholders and aims to protect investors' rights against deceit and fraud in business practices [3]